Key result
B-type natriuretic peptide testing showed high diagnostic accuracy for congestive heart failure, with an overall sensitivity of 81%, specificity of 86%, and an area under the S-ROC curve of 0.92.
Why the study?
Does B-type natriuretic peptide (BNP) testing accurately diagnose congestive heart failure in various clinical settings?
Meta-Analysis (n=11,054)
Does B-type natriuretic peptide (BNP) testing accurately diagnose congestive heart failure in various clinical settings?
BNP testing demonstrates high diagnostic accuracy for congestive heart failure, particularly in patients presenting to the emergency department with dyspnea.
Answers are grounded in this paper and cite their sources.
Supports BNP testing for acute HF diagnosis in dyspneic patients; reinforces pooled diagnostic accuracy across settings.
Background: B-type natriuretic peptide (BNP) is a neurohormone released from the left ventricle in response to ventricular wall stress and pressure overload. BNP testing has been developed, and aids in identification of patients with suspected congestive heart failure (CHF). The objective of this study was to evaluate the role of BNP as a diagnostic marker of CHF, and determine its value in different clinical settings. Methods: A systematic review and meta-analysis of clinical studies regarding BNP and CHF was conducted. A comprehensive search of Medline, the Cochrane Library, and the reference sections of the primary studies was done. The methodologic quality of each study that met the inclusion criteria was assessed. The results of individual studies were described. The pooled sensitivity and specificity were calculated. Estimation of the diagnostic accuracy was done using meta-regression of the diagnostic odds ratio and summarized by a summary receiver-operating curve (S-ROC). Results: In total, 32 studies (n = 11054) met the inclusion criteria. The overall sensitivity and specificity at the optimum cutoff point are 81% (95% confidence interval: 0.76–0.86) and 86% (95% confidence interval: 0.81–0.89), respectively. The area under the S-ROC for all studies is 0.92. Nine papers included patients with dyspnea. The pooled negative likelihood ratio for this group was 0.12. Five studies included patients with chronic CHF and another seven studies included patients who were referred for echocardiography. The remaining studies were patients from the general population, patients with stable coronary artery disease, and patients referred for cardiac catheterization. Conclusion: BNP is a valuable tool in the diagnosis of CHF. It should be applied in the appropriate clinical setting. The strongest evidence of benefit for use of BNP is in patients presenting to the emergency room with dyspnea.
No takes yet. Share an insight, caveat, or question.
Elkhateeb et al. (2010) conducted a meta-analysis in Congestive heart failure (n=11,054). B-type natriuretic peptide (BNP) testing was evaluated on Diagnosis of congestive heart failure (sensitivity and specificity) (Sensitivity 81%, 95% CI 0.76-0.86). B-type natriuretic peptide testing showed high diagnostic accuracy for congestive heart failure, with an overall sensitivity of 81%, specificity of 86%, and an area under the S-ROC curve of 0.92.
Synapse has enriched 10 related papers. Consider them for comparative context: